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Background: Parasite-derived molecules with immunomodulatory properties, which have been optimised during
host-parasite co-evolution, exhibit potential applications as novel immunotherapeutics. We have previously
demonstrated that Schistosoma japonicum HSP60-derived peptide SJMHE1 induces CD4+CD25+ regulatory T-cells
(Tregs) and that adoptively transferred SJMHE1-induced CD4+CD25+ Tregs inhibit delayed-type hypersensitivity
(DTH) in mice. However, multiple concerns regarding this method render this treatment unsuitable. To gain further
insights into the potential effects of SJMHE1, we used ovalbumin (OVA)-induced DTH and evaluated the effect of
SJMHE1 on DTH mice.
Methods: BALB/c mice were sensitised with OVA alone or combined with SJMHE1 and then challenged with OVA
to induce DTH. We first analysed the potential effects of SJMHE1 by measuring DTH responses, T-cell responses,
cytokine secretion, and Treg proportions. We then evaluated the expression levels of IL-10 and TGF-β1 in CD4+CD25+
T-cells during DTH and Treg generation to identify the mechanism by which SJMHE1 suppresses DTH.
Results: SJMHE1 modulated the effector response against OVA-induced DTH and stimulated the production of the
anti-inflammatory cytokines IL-10 and TGF-β1 in immunised mice through a mechanism involving CD4+CD25+ Tregs.
SJMHE1-induced CD4+CD25+ Tregs expressed high levels of CTLA-4, IL-10, and TGF-β1, which substantially contributed
to the suppressive activity during DTH. The administration of SJMHE1 to DTH in mice led to the expansion of CD4+CD25+
Tregs from CD4+CD25− T-cells in the periphery, which inhibited DTH responses.
Conclusions: Our study proves that the parasite-driven peptide suppresses DTH in mice, which may confer a new option
for inflammation treatment.
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Helminth infections exert potent systemic immunomod-
ulatory effects on the host immune system, weakening
host response to both infectious and noninfectious anti-
gens [1, 2]. The capacity of helminth parasites to modu-
late the immune system underpins their longevity in the
mammalian host [3–5]. The remarkable range of
parasite life histories, transmission strategies, and* Correspondence: wangxuefeng1023@126.com
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nomodulatory activities observed [3, 6, 7]. For instance,
schistosome infections lead to antigen-specific unre-
sponsiveness in the peripheral T-cell populations of
heavily infected patients [8, 9]. Moreover, concurrent
helminth infection decreases the response to bystander
allergens and autoantigens in both model systems and
human studies [1, 10, 11]. Thus, a comparison of the
mechanisms of laboratory-based rodent-helminth model
system with clinical assessment of individuals infected
with helminth parasites could reveal ways to manipulate
the human immune system to treat auto-immune and
inflammatory diseases. This process has been clinicallyis distributed under the terms of the Creative Commons Attribution 4.0
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eases or allergic diseases are being deliberately infected
with parasitic worms to evaluate their therapeutic use.
Existing findings clearly indicate that infection with
helminth parasites can reduce the severity of these
diseases [12–14].
Instead of infecting people with pathogens, which pre-
disposes them to the inevitable risk of side effects, a more
responsible approach is to identify the immunomodula-
tory molecules that selectively mimic the desirable effects
of infection and use them as a novel therapeutic approach
[6, 15, 16]. Data from animal models (and to a lesser ex-
tent, human studies) show that helminths release products
that interfere with the development of allergic responses
and inflammatory diseases [11, 17, 18]. Considerable stud-
ies have focused on identifying novel products that exhibit
similar properties. Beneficial products are expected to be
identified, characterised, and tested in vivo in the near
future.
Schistosomiasis is a typical helminth infection that in-
duces immunomodulation [19, 20]. Infection with schis-
tosomes or exposure to schistosome-derived antigens
prevents the occurrence of various auto-immune disor-
ders and atopic diseases [21–23]. Mechanistically, mole-
cules produced by a schistosome at different stages of its
life-cycle in the mammalian host can potentially inhibit
both auto-immune and inflammatory diseases through
various mechanisms [19]. We identified an HSP60-
derived peptide SJMHE1 from Schistosoma japonicum
and demonstrated that SJMHE1 stimulates IL-10 and
TGF-β, as well as inhibits IL-12 and TNF-α production
by macrophages and dendritic cells, leading to the devel-
opment of CD4+CD25+ Tregs. Using an adoptive trans-
fer model, we further demonstrated that SJMHE1
inhibits DTH by inducing CD4+CD25+ Tregs [24]. How-
ever, isolation of peptide-induced Treg populations re-
quires highly specialised facilities, and the procedure can
entail high costs [25]. Thus, immunotherapy based on
the peptide induction of Tregs may have limited thera-
peutic potential.
We investigated the potential effects of SJMHE1 on
ovalbumin (OVA)-induced DTH to develop the medical
potential of the therapeutic peptide and to elucidate the
mechanism by which SJMHE1-induced CD4+CD25+
cells downregulate DTH responses. Results showed that
SJMHE1 modulated the effector response against OVA-
induced DTH and induced the production of the anti-
inflammatory cytokines IL-10 and TGF-β1 in mice
sensitised with OVA combined with SJMHE1. The
modulation of the immune response to OVA by
SJMHE1 resulted from the induction of CD4+CD25+
Tregs. The administration of SJMHE1 to DTH mice led
to the expansion of CD4+CD25+ Tregs from CD4+CD25−
T-cells in the periphery, which inhibited DTH responses.These findings may provide useful information for explor-




Animal experiments were performed in strict accordance
with the Regulations for the Administration of Affairs
Concerning Experimental Animals (1988.11.1), and efforts
were exerted to minimise the suffering of the animals. All
animal procedures were approved by the Institutional
Animal Care and Use Committee (IACUC) of Jiangsu
University for the use of laboratory animals (Permit Num-
ber: JSU 13-027).
Mice
Eight-week-old female BALB/c mice were purchased
from the SLAC Laboratory (Shanghai, China). All animal
experiments were conducted in accordance with the
Chinese laws for animal protection and with the experi-
mental guidelines and procedures approved by the
IACUC of Jiangsu University for the use of laboratory
animals.
Peptides
SjHSP60 437-460 (SJMHE1) (VPGGGTALLR-
CIPVLDTLSTKNED) was synthesised and purified by
Top-peptide (Shanghai, China). The purity of the pep-
tides was determined to be greater than 99 % by mass
spectrometry. SJMHE1 was pretreated with polymyxin
B-agarose in accordance with a previously described
method [26] to exclude possible LPS contamination.
DTH induction and assessment
Each mouse was primed in the rear footpad with 100 μg
of OVA (fraction V; Sigma, Poole, UK) alone or com-
bined with 10, 20, or 30 μg of SJMHE1 emulsified with
complete Freund’s adjuvant (Sigma) in 100 μL. The con-
trol group received 100 μL of equal mixtures of PBS and
CFA. Seven days after sensitisation, the mice were chal-
lenged with the subcutaneous injection of 20 μL of OVA
(1 mg/mL in PBS) in the left ear and 20 μL of PBS in
the right ear. The dosage and volume of OVA for sensi-
tisation and challenge were based on previous studies
[24, 27]. DTH was assessed by measuring the thickness
of the challenged ear before and 24 h after the chal-
lenge in a blind manner with the use of a micrometer
(Mitutoyo, Osaka, Japan).
Mice were sacrificed 24 h post-challenge, and their
ears were removed. The ear tissues were homogenised
for cytokine measurement.
For CD4+CD25+ T-cell depletion, BALB/c mice were
treated intraperitoneally with 500 μg of the anti-CD25
monoclonal antibody clone PC61 (BD Bioscience,
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isation with OVA as previously described [28]. Depletion
efficiency was verified by flow cytometry (FCM) as previ-
ously described [29].
Cell isolation
Single-cell suspensions were prepared from the pooled
lymph nodes (LNs) and spleens of six mice per group
in RPMI 1640 containing 10 % FCS. CD4+CD25+ and
CD4+CD25− cell populations were separated using a
mouse Treg isolation kit (Miltenyi Biotec, Auburn, CA,
USA) in accordance with the manufacturer’s instructions.
The purity of the resulting CD4+CD25+ and CD4+CD25−
populations was routinely 95–98 %, as determined by
FCM. APCs were obtained and irradiated from single-cell
suspensions in accordance with a previously described
method [24].
Cell culture
For the proliferation assay, one day after OVA challenge,
cell suspensions were generated from the pooled LN and
spleens from individual mice as described above. Cells
were incubated in RPMI-1640 containing 10 % FCS,
2 mM L-glutamine, 100 U/mL penicillin, 100 mg/mL
streptomycin, and 1.25 mg/mL amphotericin B (all
Gibco BRL, CA, USA) (complete medium) in the pres-
ence of 1, 10, and 100 mg/mL OVA at 37 °C in 5 %
CO2. Cell proliferation was evaluated by [
3H] thymidine
(3H-TdR) incorporation. Cytokine content was analysed
in culture supernatants by ELISA from Bender Med Sys-
tems, Vienna, Austria.
For suppression assays, 1 × 105 CD4+CD25− T-cells/
well, 5 × 104 CD4+CD25+ T-cells/well, or both popula-
tions were cultured in 96-well U-bottom plates with
1 × 105 APCs/well for 72 h at 37 °C in complete
RPMI 1640 medium (0.2 mL/well) in triplicate. Cul-
tures were stimulated with 1 μg/mL soluble anti-CD3
(BD PharMingen, San Diego, CA, USA) with or with-
out 0.1 μg/mL SJMHE1. Certain wells were added
with 3 μg/mL rat IgG1 anti-mouse IL-10 (Biolegend
Inc., San Diego, CA, USA), 0.5 μg/mL rat IgG1 anti-
mouse TGF-β1 (US Biological, Swampscott, MA,
USA), or 3 μg/mL rat IgG1 (Biolegend). Proliferation
was assessed by incubation with 0.5 μCi/well 3H-thy-
midine and measuring the incorporation during the
final 16 h of culture.
Cytokine quantitation
TNF-α, IL-12, IL-10, and TGF-β1 in the supernatants of
splenic lymphocyte stimulated by 100 μg/mL OVA or in
the supernatants of homogenised ear were analysed using
an ELISA kit (Bender Med Systems, Vienna, Austria) in
accordance with the manufacturer’s instructions.Flow cytometry
The Mouse Regulatory T-Cell Staining Kit
(eBioscience, San Diego, CA, USA) was used. To analyse
CD4+CD25+Foxp3+ or CD4+CD25+CTLA4+ T-cells,
splenic and LN cells were pooled from the mice treated
with PBS, sensitised to OVA alone, or sensitised to OVA
and 30 μg of SJMHE1. They were surface-stained with
PerCP anti-CD3 mAbs (eBioscience, San Diego, CA,
USA), FITC anti-CD4 mAbs, APC anti-CD25 mAbs, and
PE anti-CTLA4. Certain cells were fixed, and then per-
meabilised with Cytofix/Cytoperm. Finally, they were
stained intracellularly with phycoerythrin (PE) mouse
anti-Foxp3 or PE IgG2a rat immunoglobulin control anti-
body in accordance with the manufacturer’s instructions.
To detect intracellular cytokines, splenic and LN cells
from mice that were treated with PBS, sensitised to
OVA alone, or sensitised to OVA and 30 μg of SJMHE1
were stimulated in the presence of PMA (25 ng/mL),
ionomycin (1 μg/mL), and GolgiStop™ (0.66 μL/mL) at
2 × 106/mL (2 mL/well) in 24-well plates for 6 h at 37 °C
in 5 % CO2. After incubation with anti-CD3-PerCP, anti-
CD4-FITC, and anti-CD25-APC mAbs, the cells were
washed, fixed, and then permeabilised with Cytofix/
Cytoperm solution (BD PharMingen). The cells were
stained intracellularly with PE-conjugated anti-IL-10
mAb (0.2 mg/mL), anti-TGF-β1 mAb (0.5 mg/mL), or
rat IgG1 (isotype control) for 1 h at room temperature.
Finally, the cells were washed in FACS buffer (PBS, 2 %
FCS and 0.05 % sodium azide) and then analysed with
the FACS Calibur (Becton Dickinson, San Jose, CA) by
using the CellQuest software (BD Biosciences).Statistical analysis
Statistical analysis was performed using GraphPad Prism
5.01 (GraphPad Software, 2007, La Jolla, CA, USA).
Statistical significance was determined using Student’s
t-test at the P < 0.05 level.Results
SHMHE1 suppressed DTH responses and modulated local
cytokine secretion
To examine whether or not SJMHE1 can modulate
DTH responses against the unrelated protein OVA,
BALB/c mice were sensitised in the rear footpad with
OVA alone or combined with SJMHE1 emulsified in
complete Freund’s adjuvant. After seven days, each
mouse was challenged in the left ear with OVA. Moni-
toring of the subsequent swelling in the challenged ear
showed that sensitisation and challenge with OVA re-
sulted in the pronounced thickening of the ear, which
signified DTH response. Sensitisation in the presence of
SJMHE1 significantly suppressed DTH responses. This
effect was dose dependent, and 30 μg of SJMHE1
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DTH (Fig. 1a).
Local cytokine production in the DTH ears was mea-
sured to analyse further the in vivo immune suppression
induced by SJMHE1. The ears were removed and homo-
genised 24 h after the challenge; multiple cytokines were
then measured. Considering that 30 μg of SJMHE1 in-
duced the strongest inhibition of DTH response, we in-
vestigated local cytokine production in the DTH ears
from mice primed with OVA alone or combined with
30 μg of SJMHE1. The cytokine levels in the control ears
from PBS mice were undetectable (Fig. 1b). By contrast,
elevated levels of pro-inflammatory cytokines (TNF-α and
IL-12) were detected in the DTH ear primed and chal-
lenged with OVA alone. Priming in the presence of
SJMHE1 significantly inhibited the local production of
TNF-α (t = 25.09, P < 0.001) and IL-12 (t = 12.64, P < 0.001)
but induced high levels of the anti-inflammatory cyto-
kines IL-10 (t = 6.485, P < 0.001) and TGF-β1 (t = 7.723,
P < 0.001) (Fig. 1b). These results suggest that SJMHE1
can suppress DTH, reduce local pro-inflammatory cyto-
kines, and increase local anti-inflammatory cytokines.
SJMHE1 modulated OVA-specific T-cell responses and
cytokine secretion in DTH mice
Examination of local pro-inflammatory cytokine produc-
tion strongly suggested that exposure to SJMHE1 in vivo
altered the effector properties of OVA-specific T-cells.Fig. 1 Suppression of DTH responses by SJMHE1. a BALB/c mice were sens
(as indicated). Challenge with OVA occurred 7 days later, and the DTH resp
thickness. The DTH responses are expressed as the mean ± SD of 12 mice f
with OVA alone or combined with 30 μg of SJMHE1. Challenge with OVA o
and homogenised. Cytokine levels in the supernatants were measured from
mice from two independent experiments. Asterisks indicate significant diffe
**P < 0.01; ***P < 0.001)Therefore, OVA-specific T-cell proliferation and cyto-
kine production were examined after stimulation by
OVA ex vivo to characterise further the functional
phenotype of OVA-specific T-cells from mice that were
primed and challenged by OVA alone or combined with
SJMHE1. As shown in Fig. 2a, splenic lymphocytes from
mice primed with only OVA showed a dose-dependent
proliferation profile. However, the splenic lymphocytes
from mice primed with OVA combined with 30 μg of
SJMHE1 exhibited significantly reduced proliferative
capacity after OVA stimulation ex vivo (1 μg/mL OVA
stimulation: t = 18.57, P < 0.001; 10 μg/mL OVA stimu-
lation: t = 15.78, P < 0.001; 100 μg/mL OVA stimulation:
t = 17.78, P < 0.001; Fig. 2a). Therefore, OVA combined
with SJMHE1 elicited a more observable OVA-specific
T-cell unresponsiveness compared with the other treatments.
Splenic lymphocytes were cultured ex vivo with
100 μg/mL OVA to evaluate the effects of SJMHE1
treatment on cytokine secretion by T-cells. The levels of
TNF-α, IL-12, IL-10, and TGF-β1 were measured in the
culture supernatant through ELISA. As shown in Fig. 2b,
the splenic lymphocytes from mice primed with only
OVA secreted large amounts of TNF-α and IL-12 in re-
sponse to OVA but produced minimal IL-10 and TGF-
β1. Meanwhile, the splenic lymphocytes from mice
primed with OVA combined with SJMHE1 produced
high levels of IL-10 (t = 6.749, P < 0.001) and TGF-β1
(t = 6.725, P < 0.001) but decreased levels of TNF-αitised with OVA alone or combined with various amounts of SJMHE1
onses were assessed over the subsequent 24 h with the change in ear
rom two independent experiments; b BALB/c mice were sensitised
ccurred 7 days later; 24 h after the challenge, the ear was removed
the homogenised tissue. Data are shown as the mean ± SD of 12
rences analysed using Student’s t-test (*P < 0.05;
Fig. 2 SJMHE1 modulated OVA-specific T-cell responses and cytokine secretion in DTH mice. a BALB/c mice were sensitised with OVA alone or
combined with 30 μg of SJMHE1. Challenge with OVA occurred 7 days later, and pooled splenic and LN cells from these mice were prepared
1 day after the challenge. The cells were cultured in complete RPMI 1640 at 5 × 105 cells/well with OVA for 3 days, and proliferation was
measured by 3H-thymidine incorporation. Data are expressed as the mean values of two experiments with six mice per group; b Cells
were cultured at 5 × 105 cells/well stimulated by 100 μg/mL OVA for 3 days, and the cytokines in culture supernatants were analysed by
ELISA. Data are displayed as the mean ± SD from two experiments performed in triplicate. Asterisks indicate significant differences analysed using the
independent Student’s t-test (**P < 0.01; ***P < 0.001)
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These findings suggest that SJMHE1 induces anti-
inflammatory cytokines (IL-10 and TGF-β1) to protect
against DTH. Overall, SJMHE1 induces an OVA-specific
T-cell unresponsiveness and anti-inflammatory environ-
ment to weaken the pro-inflammatory response and thus
protect against DTH.
SJMHE1 increased CD4+CD25+ Foxp3+ Treg proportions in
DTH mice
Previous reports suggested that soluble mediators
such as IL-10 and TGF-β1 contribute to the induction
of CD4+CD25+ Tregs [29, 30], which consequently se-
crete IL-10 and/or TGF-β1 to enhance the inhibition
of DTH responses [25, 29]. SJMHE1 induces the
ex vivo production of regulatory cytokines IL-10 and
TGF-β1 in DTH mice, and SJMHE1 treatment in-
creases CD4+CD25+ Tregs both in vivo and in vitro
[24]. Thus, we assumed that the inhibition of DTH
responses in mice treated with SJMHE1 is potentially
associated with CD4+CD25+ Tregs induced by SJMHE1.
We then tested the CD4+CD25+FoxP3+ T-cells from mice
treated with OVA alone or combined with SJMHE1.
As shown in Fig. 3a and c, the proportion of
CD4+CD25+FoxP3+ T-cells significantly increased in the
spleens and LNs of the mice sensitised with OVA combined
with SJMHE1 compared with those of the mice sensitisedwith OVA alone (t = 8.785, P < 0.001) or treated with PBS
(t = 10.17, P < 0.001). SJMHE1 treatment upregulated the
expression of a regulatory characteristic marker (cytotoxic
T lymphocyte antigen 4, CTLA-4) on CD4+CD25+ T-cells
(OVA vs OVA + SJMHE1: t = 8.404, P < 0.001; PBS vs
OVA + SJMHE1: t = 12.52, P < 0.001; Fig. 3b and d).
Overall, SJMHE1 promotes the generation of activated
CD4+CD25+ Tregs during DTH.
SJMHE1 induced IL-10 and TGF-β1 expression in CD4+CD25+
T-cells during DTH
Splenic lymphocytes from mice immunised with OVA
combined with SJMHE1 produced high levels of anti-
inflammatory cytokines (IL-10 and TGF-β1). Thus, we
determined the relationship of the upregulated IL-10
and TGF-β1 in SJMHE1-treated mice with the SJMHE1-
induced CD4+CD25+ T-cells. We further investigated
the expression of intracellular IL-10 and TGF-β1 in the
CD4+CD25+ T-cells from mice sensitised with OVA
alone or combined with SJMHE1. Flow cytometric ana-
lysis revealed higher expression levels of intracellular IL-
10 (t = 11.18, P < 0.001) and TGF-β1 (t = 10.10, P < 0.001)
in the CD4+CD25+ T-cells from SJMHE1-immunised
mice than in those from OVA-injected mice (Fig. 4).
These results indicate that the production of IL-10 and
TGF-β1 by CD4+CD25+ T-cells contributes to SJMHE1-
mediated inhibition.
Fig. 3 SJMHE1 increased CD4+CD25+ Foxp3+ T-cells in DTH mice. BALB/c mice were sensitised with OVA alone or combined with 30 μg of
SJMHE1. Challenge with OVA occurred 7 days later; 24 h after the challenge, spleen and LNs from each mouse were pooled. Single-cell suspensions
were prepared, and red blood cells were lysed. a Flow cytometry for CD3, CD4, CD25, and Foxp3 was performed, and data are expressed
as the mean ± SD of 18 mice from three independent experiments; b Flow cytometry for CD3, CD4, CD25, and CTLA4 was performed.
Data are expressed as the mean ± SD of 18 mice from three independent experiments; c Analysis of CD4+CD25+Foxp3+ T-cells from
pooled splenic and LN cells by flow cytometry. Data are representative of the experiments; d Analysis of CD4+CD25+CTLA4+ T-cells from
pooled spleen and LN cells by flow cytometry. Data are representative of the experiments. Values indicate the percentage of events in
the indicated quadrant. Asterisks indicate significant differences analysed using the independent Student’s t-test (***P < 0.001)
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of responder T-cells from DTH mice by SJMHE1-induced
CD4+CD25+ Tregs
We used CD4+CD25+ cells from either SJMHE1- or
PBS-treated mice to assess further the suppressive effi-
cacy of SJMHE1-induced CD4+CD25+ Tregs. Each of
the two groups of enriched CD4+CD25+ cells was co-
incubated with the CD4+CD25− T-cells from mice
primed and challenged with OVA alone (established
DTH mice). As shown in Fig. 5a, the CD4+CD25+ T-
cells from the two immunised mouse groups were highly
effective in suppressing CD4+CD25− T-cell prolifera-
tion after stimulation with anti-CD3 Ab. However, the
CD4+CD25+ T-cells purified from SJMHE1-immunised
mice induced the highest inhibition. Compared with
the CD4+CD25+ T-cells purified from PBS-immunisedmice, the CD4+CD25+ T-cells generated from SJMHE1-
immunised mice showed significantly enhanced inhibitory
ability after the addition of SJMHE1 to co-cultures
(t = 7.232, P < 0.001).
Considering that the SJMHE1-induced CD4+CD25+ T-
cells secreted both IL-10 and TGF-β1, we tested whether
or not these cytokines mediate the suppressor function
of CD4+CD25+ T-cells ex vivo. The CD4+CD25− T-cells
from the mice primed and challenged with OVA alone
(established DTH mice) were co-incubated with
SJMHE1-induced CD4+CD25+ T-cells with or without
anti-IL-10, anti-TGF-β1 neutralizing mAb, or a mixture
of anti-IL-10, anti-TGF-β1, or their IgG1 isotype con-
trols. As shown in Fig. 5b, the ex vivo suppressive activ-
ities of CD4+CD25+ T-cells were partially reversed by
the addition of anti-IL-10 or anti-TGF-β1 mAb to the
Fig. 4 SJMHE1 induced IL-10 and TGF-β1 expression in CD4+CD25+ T-cells during DTH. a BALB/c mice were sensitised with OVA alone or combined
with 30 μg of SJMHE1. Challenge with OVA occurred 7 days later; 24 h after the challenge, spleen and LNs from each mouse were pooled. Single-cell
suspensions were prepared, and red blood cells were lysed. Intracellular expression levels of IL-10 and TGF-β1 were analysed by flow cytometry. Events
were gated on CD3, CD4, and CD25 expression as indicated. Values indicate the percentage of events in the indicated quadrant. Data are expressed as
the mean ± SD of 18 mice from three independent experiments; b Expression of intracellular IL-10 and TGF-β1 in gated CD4+CD25+ cells was analysed
by flow cytometry. Data are representative of the experiments. Asterisks indicate significant differences analysed using the independent Student’s
t-test (***P < 0.001)
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SJMHE1-induced CD4+CD25+ T-cells partly mediate
their suppressive effects via IL-10 or TGF-β1. How-
ever, the mixture of anti-IL-10 and anti-TGF-β1 mAb
completely blocked the suppressive activity mediated
by CD4+CD25+ T-cells (t = 14.05, P < 0.001). These re-
sults suggest that both IL-10 and TGF-β1 mediate the
inhibition of CD4+CD25+ T-cells induced by SJMHE1
during DTH.
SJMHE1 induced the generation of peripheral CD4+CD25+
Tregs from CD4+CD25− T-cells
CD4+CD25+ Tregs can be generated peripherally from
CD4+CD25− T-cells [31]. We performed depletion ex-
periments of CD4+CD25+ T-cells to determine whether
or not the SJMHE1-induced increase in CD4+CD25+
Tregs during DTH is attributable to the expansion of
the existing naturally occurring CD4+CD25+ Tregs or to
newly generated Tregs from CD4+CD25− T-cells. The
mice were injected with anti-mouse CD25 mAb, and the
depletion of CD25-expressing cells was confirmed usingFACS. After 24 h, the mice were primed and challenged
to induce DTH. We tested the CD4+CD25+FoxP3+ T-
cells from mice in each group 24 h after the challenge.
As shown in Fig. 6a, the depletion of CD25+ T-cells
prior to OVA immunisation enhanced the severity of
DTH responses as compared with the mice immunised
with OVA alone or combined SJMHE1. The proportion
of CD4+CD25+Foxp3+ T-cells significantly increased in
the spleens and LN of the SJMHE1-administered mice
than in those of the OVA-immunised (t = 8.486, P < 0.001)
or PBS-treated mice (t = 9.709, P < 0.001) regardless of
the depletion of CD25+ T-cells (Fig. 6b and c). CD25+
depletion exerted no influence on the beneficial effect
of SJMHE1. The mice depleted of CD25+ T-cells and
immunised with OVA and SJMHE1 possessed almost the
same number of spleen and lymph CD4+CD25+Foxp3+ T-
cells as the SJMHE1-treated undepleted mice (Fig. 6b
and c). The results suggest that SJMHE1 induces the gener-
ation of peripheral CD4+CD25+ Tregs from CD4+CD25−
T-cells. To confirm this hypothesis, CD4+CD25− T-cells
isolated from the spleen and LNs of DTH mice were
Fig. 5 IL-10 and TGF-β1 mediated the inhibition of the proliferation
of responder T-cells from DTH mice by SJMHE1-induced CD4+CD25+
Tregs. a Responder CD4+CD25− T-cells (1 × 105 cells/well) and
irradiated APCs (1 × 105 cells/well) from DTH mice (primed and
challenged with OVA alone) were cultured with CD4+CD25+ T-cells
(5 × 104 cells/well) harvested from either SJMHE1- or PBS-treated mice
and stimulated with anti-CD3 (1 μg/mL) in the presence or absence of
SJMHE1 (0.1 μg/mL); b CD4+CD25− T-cells (1 × 105 cells/well) and
irradiated APCs (1 × 105 cells/well) from DTH mice were cultured for
72 h either alone or with CD4+CD25+ T-cells (5 × 104 cells/well) from
SJMHE1-immunised mice and stimulated with anti-CD3 (1 μg/mL).
Wells contained either anti-IL-10 (3 μg/mL), anti-TGF-β1 (0.5 μg/mL),
both antibodies, or isotype control antibodies. Proliferation was
measured by 3H-thymidine incorporation for the last 16 h of the
experiment. Data are shown as the mean ± SD (n = 6 per group)
from three independent experiments. Asterisks indicate significant
differences analysed using the independent Student’s t-test
(***P < 0.001)
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of APCs. As shown in Fig. 6d and e, the incubation with
SJMHE1 significantly increased the percentage of
CD4+CD25+Foxp3+ T-cells in an APC-dependent manner
(t = 9.802, P < 0.001). This result suggests that SJMHE1 in-
duces the peripheral generation of CD4+CD25+Foxp3+
T-cells from the CD4+CD25− compartment.
Discussion
Parasite such as Schistosoma mansoni have co-evolved
with the immune systems of their mammalian hosts;
thus, they have established a strong regulatory and anti-
inflammatory network to ensure their safety inside thesehosts [19, 32–34]. Schistosome infection modulates the
progression of autoimmune diseases, such as experimen-
tal colitis [12], experimental allergic encephalomyelitis
[35], Graves’ disease [36], and type 1 diabetes [37]. Thus,
considerable interest has been drawn toward defining
the molecules derived from schistosomes, which can re-
place live infection to prevent or control pro-inflammatory
pathological responses [19]. Furthermore, identifying and
characterising immunomodulatory molecules from various
pathogens is an expanding area of research that should
provide an opportunity to uncover many natural inflam-
mation modulators with the potential for use as novel
immunotherapeutics to treat immune-mediated human
diseases [15, 16].
In that regard, some parasite-derived immunomodula-
tors from helminths have recently been reported [15].
The most well-defined nematode-derived immunomodu-
latory molecule to date is ES-62, a phosphorylcholine-
containing glycoprotein secreted by the rodent filarial
nematode Acanthocheilonema viteae. This molecule has
well-conserved orthologs in human filarial nematode
parasites, including Brugia malayi and Onchocerca vol-
vulus [13, 17, 38, 39]. ES-62 exhibits a wide range of
anti-inflammatory properties [40–42]; thus, the molecule
has been tested in mouse models of both autoimmune
and allergic diseases and has been reported to protect
against collagen-induced arthritis [42, 43] and type I
hypersensitivity in the skin and lungs [44].
The most important finding of the current study is that
the administration of the parasite-derived immunomodu-
latory molecule SJMHE1 from S. japonicum can inhibit
DTH responses in a mouse model. SJMHE1 is composed
of overlapping T-cell epitopes and is highly identical to
murine and human HSP60. Consistent with the previous
observation, the “share epitope” cross-recognition of auto-
reactive T-cells reportedly protects against autoimmune
and inflammatory disorders in experimental animal
models [45, 46]. The combination of OVA and SJMHE1
more greatly suppressed DTH responses to a single OVA
challenge compared with OVA alone. The attenuation of
inflammation in DTH mice by SJMHE1 treatment was as-
sociated with a reduction in pro-inflammatory cytokines
(TNF-α and IL-12) and a concomitant increase in anti-
inflammatory cytokine production (IL-10 and TGF-β1) by
inflammatory sites and T-cells. Increased IL-10 and TGF-
β1 production from both the local inflammatory sites and
by ex vivo splenic T-cells indicate that SJMHE1-stimulated
immunomodulatory responses occur both in local and
systemic tissues. These results are consistent with other
parasite products, such as body fluid from Ascaris suum
(ABF), which suppresses DTH responses in mice by co-
immunisation with OVA at the time of priming. This sup-
pression was partially mediated by the anti-inflammatory
cytokine IL-10 [47].
Fig. 6 SJMHE1 induced the generation of peripheral CD4+CD25+ Tregs from CD4+CD25− T-cells. BALB/c mice were injected with anti-CD25 Ab to
eliminate CD25+ T-cells and sensitised with OVA alone or combined with 30 μg of SJMHE1 after 24 h. a DTH responses were assessed over the
subsequent 24 h with the change in ear thickness. DTH responses are expressed as the mean ± SD of 12 mice from two independent experiments;
b Challenge with OVA occurred 7 days later; 24 h after the challenge, spleen and LNs from each mouse were pooled. FCM analysis for CD3, CD4,
CD25, and Foxp3 was performed, and data are expressed as the mean ± SD of 18 mice from three independent experiments; c One representative
experiment of the total data shown in b; d Splenic CD4+CD25− T-cells (2 × 105/well) isolated from DTH mice (primed and challenged with OVA alone)
were stimulated with 0.1 μg/mL SJMHE1 in the absence or presence of APC (2 × 105/well) for 3 days. The cells were stained with PerCP-anti-CD3,
FITC-anti-CD4, APC-anti-CD25, and PE-anti-Foxp3 and then examined by flow cytometry. Data are expressed as the mean ± SD of two independent
experiments (n = 6 per group); e Representative experiment of the total data shown in d. Asterisks indicate significant differences analysed using the
independent Student’s t-test. (**P < 0.01; ***P < 0.001)
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of peripheral tolerance and the control of the immune
response. Consistent with SJMHE1 treatment leading to
the increase in the population of CD4+CD25+Foxp3+ T-
cells [24], SJMHE1 induced the generation and/or
activation of CD4+CD25+ Tregs during DTH; this
phenomenon suppressed the inflammatory response in
DTH mice. In addition to expanding the CD4+CD25+
Treg population, SJMHE1 also induced Tregs efficient in
both cytokine secretion and suppressive activity. A char-
acteristic marker of Tregs is the constitutive expression
of CTLA-4, a negative regulatory factor critical for theinduction and function of Tregs [48, 49]. Consistent
with these reports, SJMHE1-induced CD4+CD25+ Tregs
expressed high levels of CTLA-4, explaining the partial
dependence of the regulatory activity of these cells.
SJMHE1-induced CD4+CD25+ Tregs also produced high
levels of IL-10 and TGF-β1, which significantly contrib-
ute to the suppressive properties of CD4+CD25+ T-cells
ex vivo. The mechanisms involved in the generation/ac-
tivation of Tregs by SJMHE1 during DTH are not fully
understood. However, the present study showed that
they can be peripherally generated from CD4+CD25− T-
cells because SJMHE1 administration inhibited DTH
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ber of CD4+CD25+ Tregs. In addition, SJMHE1 induced
the ex vivo generation of CD4+CD25+Foxp3+ T-cells
from activated CD4+CD25− T-cells of DTH mice in an
APC-dependent manner. These data are consistent with
our previous finding that SJMHE1 induces the differenti-
ation of tolerogenic DCs and MΦs with the capacity to
generate CD4+CD25+ Tregs in vitro [24]. Therefore, we
hypothesised that SJMHE1 can generate CD4+CD25+
Tregs from the peripheral CD4+CD25− compartment by
inducing tolerogenic APCs and augment IL-10 and
TGF-β production in DTH mice. The production of IL-
10 and TGF-β might further promote the development
of Tregs [19]. The cooperation between Tregs and the
anti-inflammatory cytokines IL-10 and TGF-β1 would
contribute to the therapeutic effect of SJMHE1 on auto-
immune and inflammation disorders. Furthermore, these
“safe” selective generated anti-inflammatory signals,
which have evolved during host-parasite interactions, can
be used to provide unique tools for defining key molecular
events in the development of an anti-inflammatory re-
sponse and for defining new therapeutic targets [50].
Considerable effort has recently been directed toward
the enhancement or restoration of Treg functions for
therapeutic immunointervention in autoimmune and in-
flammatory diseases. Therapeutic restoration or boosting
of the Treg compartment in vivo by small-molecule or
biopharmaceutical therapeutics would allow for such a
treatment to be more affordable and more widely avail-
able than customised Treg therapy. In favor of such a
strategy, several experimental models have demonstrated
that many immunosuppressive peptides could elicit Treg
development in the periphery and protect against auto-
immune diseases, such as collagen-induced arthritis [51],
myasthenia gravis [52], and multiple sclerosis [53]. The
inhibition of DTH responses by SJMHE1 in the current
study is consistent with previous results indicating that
the active suppression by other peptides is mediated by
the induction of CD4+CD25+ Tregs, the downregulation
of inflammatory cytokines, and the upregulation of IL-10
and TGF-β1 secretion [54, 55]. The potential use of
SJMHE1 as a therapeutic peptide for the treatment of al-
lergic and autoimmune diseases requires further analysis.Conclusions
The HSP60 peptide SJMHE1 derived from S. japonicum
can effectively inhibit DTH. SJMHE1 suppresses pro-
inflammatory cytokines, enhances anti-inflammatory
cytokine production by the cells in both the local tissues
and the immune system, and generates CD4+CD25+
Tregs that depend on the production of IL-10 and TGF-
β1 to suppress DTH responses. Thus, SJMHE1 posses-
sing immunomodulatory properties can have potentialtherapeutic applications for the treatment of inflamma-
tory disorders.
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